Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prevention of recurrent ischemic stroke.

R L Koller1

  • 1Neurological Clinic, Minneapolis, MN 55404.

Postgraduate Medicine
|December 1, 1991
PubMed
Summary

Focused prophylaxis after ischemic stroke or transient ischemic attack (TIA) targets the cause. Aspirin is standard therapy; carotid endarterectomy is recommended for severe stenosis. Anticoagulants are reserved for progressing strokes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intravenous thrombolytic therapy for acute ischemic stroke. Weighing the risks and benefits of tissue plasminogen activator.

Postgraduate medicine·1998
Same author

Cervical bruits: clinical correlates of stenosis.

Angiology·1991
Same author

Recurrent embolic cerebral infarction and anticoagulation.

Neurology·1982
Same author

Strawberry pickers' palsy.

Archives of neurology·1980
Same author

The present status of tracheotomy in bulbar poliomyelitis.

Transactions of the ... annual meeting of the American Laryngological Association. American Laryngological Association. Annual Meeting·1952
Same author

The present status of tracheotomy in bulbar poliomyelitis.

The Annals of otology, rhinology, and laryngology·1951

Area of Science:

  • Neurology
  • Vascular Medicine
  • Preventive Cardiology

Background:

  • Ischemic stroke and transient ischemic attack (TIA) management requires targeted prophylaxis based on the underlying cause.
  • Degenerative large- and small-vessel disease are common causes of ischemic stroke, necessitating a focus on modifiable risk factors.
  • Therapeutic strategies for stroke prevention are evolving, with ongoing research clarifying optimal treatments.

Purpose of the Study:

  • To review current evidence for secondary prevention strategies following ischemic stroke and TIA.
  • To delineate the role of various pharmacologic and surgical interventions in stroke prophylaxis.
  • To provide guidance on managing patients with cerebrovascular disease to reduce recurrent events.

Main Methods:

  • Review of scientific data and clinical trial evidence regarding stroke treatment and prevention.
  • Analysis of guidelines and expert consensus on managing ischemic stroke and TIA.
  • Evaluation of the efficacy and safety of medications such as aspirin, dipyridamole, ticlopidine, and anticoagulants.
  • Assessment of surgical interventions like carotid endarterectomy.

Main Results:

  • Carotid endarterectomy is strongly supported for severe stenosis (70%-99%) with ipsilateral TIA or nondisabling stroke.
  • Aspirin is recommended as standard preventive therapy for all TIA/stroke patients, with 325 mg/day potentially offering less gastrotoxicity than 1,300 mg/day.
  • Dipyridamole is not currently warranted; ticlopidine's role is undefined but may be a first-choice drug despite cost and side effects.
  • Anticoagulant efficacy is unproven for degenerative cerebrovascular disease but may be prudent for progressing strokes; immediate post-TIA heparin is not indicated.

Conclusions:

  • Secondary stroke prevention should be cause-directed, prioritizing modifiable risk factors.
  • Aspirin is a cornerstone of therapy, while carotid endarterectomy is indicated for specific severe stenosis cases.
  • The use of anticoagulants and newer antiplatelet agents requires careful consideration based on individual patient profiles and ongoing thrombotic risk.

Related Experiment Videos